Biomarker sources for Parkinson's disease: Time to shed tears?

Börger, M. Elisa; Funke, Sebastian; Bähr, Mathias; Grus, Franz H.; Lingor, Paul

doi:10.1016/j.baga.2015.05.001

Cited by 21 publications

(17 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Following this work, Börger et al [ 186 ] recently proposed the usefulness of tears as a source of PD biomarkers. The authors are currently performing a “monocentric, prospective, diagnostic trial” in which they are retrieving tear fluids from PD patients, as well as from atypical Parkinsonian syndromes, and healthy controls.…”

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 98%

“…The authors are currently performing a “monocentric, prospective, diagnostic trial” in which they are retrieving tear fluids from PD patients, as well as from atypical Parkinsonian syndromes, and healthy controls. In addition to completing clinical characterisation, all tissue samples (tear fluid, CSF and blood) will be analysed via LC ESI-MS and the authors hope this prospective study will provide an understanding of proteomic alterations in PD and thus identify novel prospective biomarkers of the condition [ 186 ].…”

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 99%

See 1 more Smart Citation

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

2016

View full text Add to dashboard Cite

In the field of predictive, preventive and personalised medicine, researchers are keen to identify novel and reliable ways to predict and diagnose disease, as well as to monitor patient response to therapeutic agents. In the last decade alone, the sensitivity of profiling technologies has undergone huge improvements in detection sensitivity, thus allowing quantification of minute samples, for example body fluids that were previously difficult to assay. As a consequence, there has been a huge increase in tear fluid investigation, predominantly in the field of ocular surface disease. As tears are a more accessible and less complex body fluid (than serum or plasma) and sampling is much less invasive, research is starting to focus on how disease processes affect the proteomic, lipidomic and metabolomic composition of the tear film. By determining compositional changes to tear profiles, crucial pathways in disease progression may be identified, allowing for more predictive and personalised therapy of the individual.This article will provide an overview of the various putative tear fluid biomarkers that have been identified to date, ranging from ocular surface disease and retinopathies to cancer and multiple sclerosis. Putative tear fluid biomarkers of ocular disorders, as well as the more recent field of systemic disease biomarkers, will be shown.

show abstract

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 98%

Section: Tear Fluid Analysis In Systemic Diseasesmentioning

confidence: 99%

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

2016

View full text Add to dashboard Cite

show abstract

“…In this regard, using peripheral blood plasma is a promising way to develop biomarkers for PD. 5 Although several studies showed that the level of different types of α-synuclein in the plasma of patients with PD could be used as a biomarker, it is still controversial whether the α-synuclein level is a suitable biomarker for PD prediction or diagnosis, due to the inconsistency of the results. 6,7 Accordingly, the peripheral α-synuclein level does not seem to have potential as a biomarker.…”

Section: What Does This Study Add To Our Know-ledge?mentioning

confidence: 99%

Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease

Kang

Kim

Heo

et al. 2020

Clinical Translational Sci

View full text Add to dashboard Cite

The current diagnosis of Parkinson’s disease (PD) mostly relies on clinical rating scales related to motor dysfunction. Given that clinical symptoms of PD appear after significant neuronal cell death in the brain, it is required to identify accessible, objective, and quantifiable biomarkers for early diagnosis of PD. In this study, a total of 20 patients with idiopathic PD and 20 age‐matched patients with essential tremor according to the UK Brain Bank Criteria were consecutively enrolled to identify peripheral blood biomarkers for PD. Clinical data were obtained by clinical survey and assessment. Using albumin‐depleted and immunoglobulin G‐depleted plasma samples, we performed immunoblot analysis of seven autophagy‐related proteins and compared the levels of proteins to those of the control group. We also analyzed the correlation between the levels of candidate proteins and clinical characteristics. Finally, we validated our biomarker models using receiver operating characteristic curve analysis. We found that the levels of BCL2‐associated athanogene 2 (BAG2) and cathepsin D were significantly decreased in plasma of patients with PD ( P = 0.009 and P = 0.0077, respectively). The level of BAG2 in patients with PD was significantly correlated with Cross‐Culture Smell Identification Test score, which indicates olfactory dysfunction. We found that our biomarker model distinguishes PD with 87.5% diagnostic accuracy (area under the curve (AUC) = 0.875, P < 0.0001). Our result suggests BAG2 and cathepsin D as candidates for early‐diagnosis plasma biomarkers for PD. We provide the possibility of plasma biomarkers related to the autophagy pathway, by which decreased levels of BAG2 and cathepsin D might lead to dysfunction of autophagy.

show abstract

“…Tear fluid sampling is a simple non-invasive procedure, in contrast to the blood or cerebrospinal fluid sampling traditionally used to screen for peripheral biomarkers [5]. However, only a few studies have been ABSTRACT An important approach to an early diagnosis of Parkinson's disease (PD) is screening for peripheral biomarkers in patients at the early clinical stage.…”

Section: Introductionmentioning

confidence: 99%

Tear Fluid Catecholamines As Biomarkers of the Parkinson’s Disease: A Clinical and Experimental Study

et al. 2019

View full text Add to dashboard Cite

An important approach to an early diagnosis of Parkinsons disease (PD) is screening for peripheral biomarkers in patients at the early clinical stage. In this study, we evaluated catecholamine concentration changes in the tear fluid of untreated PD patients as biomarkers. Norepinephrine and dopamine concentrations in the tear fluid of patients were found to increase compared to those in age controls, which was especially pronounced on the side where motor symptoms appeared. On the contrary, the epinephrine concentration in the tear fluid of patients was reduced bilaterally. Since there was no reason to consider the markers found in the clinical stage of PD as markers of the preclinical stage, we additionally studied the tear fluid composition in mouse neurotoxic models of PD preclinical and clinical stages. The norepinephrine concentration in the tear fluid of mice from the clinical stage model was found to be higher than that in controls; in the preclinical stage model, the norepinephrine concentration had a tendency to increase. Therefore, both PD patients and mice from PD preclinical and clinical stage models manifest unidirectional changes in their tear fluid compositions, which may be considered as promising biomarkers for the development of early diagnosis.

show abstract

Biomarker sources for Parkinson's disease: Time to shed tears?

Cited by 21 publications

References 85 publications

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine

Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson’s Disease

Tear Fluid Catecholamines As Biomarkers of the Parkinson’s Disease: A Clinical and Experimental Study

Contact Info

Product

Resources

About